RecruitingNCT04777916

Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

A Prospective Non-interventional Study Documenting the Management and Outcomes of Adult Patients With Acute Myeloid Leukemia (AML)

Sponsor

Acute Leukemia French Association

Enrollment

5,000 participants

Start Date

Apr 14, 2022

Study Type

OBSERVATIONAL

Conditions

Acute Myeloid Leukemia (AML)

Summary

During the last fifteen years, the landscape of AML diagnosis and therapeutical options has markedly evolved. Refined genetic and prognostic characterizations, together with new drug approvals and new allogeneic hematopoietic stem cell transplantation (HSCT) procedures, have increased patient journey diversity.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an observational registry study tracking adult patients with acute myeloid leukemia (AML — a fast-growing blood cancer) in France. It collects real-world data on newly diagnosed and relapsed/refractory patients to better understand how AML is treated in clinical practice and what outcomes patients experience. **You may be eligible if...** - You are 18 or older with a new or returning AML diagnosis - You have health insurance - You have not been previously treated for leukemia (for newly diagnosed patients), except possibly with hydroxyurea, or a prior MDS/MPN treatment before AML developed - You weigh at least 50 kg **You may NOT be eligible if...** - You have acute promyelocytic leukemia (APL) - You are opposed to participating in the study - Your AML has not been confirmed by bone marrow biopsy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(30)

Chu Amiens

Amiens, France

Centre Hospitalier Victor Dupouy

Argenteuil, France

AP-HP-GHU - Hôpital AVICENNE

Bobigny, France

CHU de la cote de Nacre

Caen, France

Hôpital MILITAIRE PERCY

Clamart, France

Centre hospitalier Sud Francilien

Corbeil-Essonnes, France

Hôpital Henri Mondor AP-HP

Créteil, France

CHU Dijon- François Mitterrand

Dijon, France

Centre Hospitalier de Dunkerque

Dunkirk, France

Centre Hospitalier de Versailles André Mignot

Le Chesnay, France

Centre Hospitalier Dr Schaffner

Lens, France

CHRU de Lille- Hopital C. HURIEZ

Lille, France

GHICL-Hopital St Vincent de Paul

Lille, France

C H U DE LIMOGES- Hopital Dupuytren

Limoges, France

CHU La Conception

Marseille, France

Centre Hopsitalier de l'Est Francilien - Site de Meaux

Meaux, France

Centre Antoine Lacassagne

Nice, France

CHU Nice,Hopital Archet 1

Nice, France

Hopital Pitié-Salpétrière APHP

Paris, France

Hôpital Necker - APHP

Paris, France

Hôpital SAINT ANTOINE-APHP

Paris, France

Hôpital Saint Louis- APHP

Paris, France

Centre Hospitalier Lyon Sud

Pierre-Bénite, France

Centre Hospitalier René Dubos

Pontoise, France

Centre Hospitalier de Roubaix

Roubaix, France

Centre Henri Becquerel

Rouen, France

Institut Curie - Hôpital René HUGUENIN

Saint-Cloud, France

Centre Hospitalier de St Quentin

Saint-Quentin, France

Centre Hospitalier Valenciennes

Valenciennes, France

Institut Gustave Roussy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04777916

Related Trials

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

NCT0590705715 locations

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT050924511 location

Ivosidenib as Post-HSCT Maintenance for AML

NCT067074934 locations

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

NCT068112331 location

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

NCT0318887460 locations